Adaptive Biotechnologies
FDA Advisors Unanimously Support Using MRD to Expedite Multiple Myeloma Drugs Through Trials
Premium
ODAC members agreed that minimal residual disease can be a reliable biomarker for accelerated approval, but sponsors must provide confirmatory evidence of clinical benefit.
JP Morgan Healthcare Conference Day 2: Bluebird Bio, Ideaya, Revolution, Relay, and More
On the second day, companies developing precision medicines and tests discussed pipeline priorities and strategic options for their businesses.
Adaptive Biotechnologies, Takeda Partner to Develop Treatments for Lymphoid Malignancies
The multiyear collaboration will use Adaptive's ClonoSeq assay to measure minimal residual disease status as an endpoint for Takeda’s clinical trials.
JP Morgan Healthcare Conference, Day 1: Novartis, Bristol Myers Squibb, Mirati, Johnson & Johnson
During the first day, Novartis discussed its future plans for Pluvicto, Mirati talked about its newly approved KRAS inhibitor Krazati, and Gilead highlighted efforts to expand use of Trodelvy.
Adaptive Biotechnologies Inks Partnership to Integrate MRD Assay With Epic's EMR System
After the expected integration in 2023, providers can order Adaptive’s ClonoSeq assay and review the results using the Epic electronic medical record system.